Pieces of the puzzle began to fall into place: IVIG, the treatment Jeff was receiving, does not work for patients with the neurofascin 155 variant of CIDP. This is because neurofascin 155 antibodies are different from other antibodies: they can bind to myelin without using the resources that IVIG targets.
Jeff brought this information to his doctors. They decided to try plasma exchange treatment instead, which filters the blood and tends to be effective against the neurofascin 155 variant of CIDP. But despite undergoing plasma exchange every two weeks, Jeff’s symptoms kept getting worse.